| [1] |
Jin B,Zeng C,Ge Y, et al. The spectrum of biopsy-proven kidney diseases in elderly Chinese patients[J]. Nephrol Dial Transplant, 2014, 29(12):2251-2259.
|
| [2] |
Chen Y,Li P,Cui C, et al. Biopsy-proven kidney diseases in the elderly: clinical characteristics, renal histopathological spectrum and prognostic factors[J]. J Int Med Res, 2016, 44(5):1092-1102.
|
| [3] |
Beck LH Jr,Bonegio RG,Lambeau G, et al. M-Type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy[J]. N Engl J Med, 2009, 361(1):11-21.
|
| [4] |
Tomas NM,Beck LH Jr,Meyer-Schwesinger C, et al. Trombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy[J]. N Engl J Med, 2014, 371(24):2277-2287.
|
| [5] |
Jhaveri KD,Shah HH,Patel C, et al. Glomerular diseases associated with cancer, chemotherapy, and hematopoietic stem cell transplantation [J]. Adv Chronic Kidney Dis, 2014, 21(1):48-55.
|
| [6] |
Jhaveri KD,Shah HH,Calderon K, et al. Glomerular diseases seen with cancer and chemotherapy: a narrative review [J]. Kidney Int, 2013, 84(1):34-44.
|
| [7] |
Nawaz FA,Larsen CP,Troxell ML, et al. Membranous nephropathy and nonsteroidal anti-inflammatory agents[J]. Am J Kidney Dis, 2013, 62(5):1012-1017.
|
| [8] |
Cameron JS. Nephrotic syndrome in the elderly [J]. Semin Nephrol, 1996, 16 (4):319-329.
|
| [9] |
Callaqhan CA,Hicks J,Doll H, et al. Characteristics and outcome of membranous nephropathy in older patients [J]. Int Urol Nephrol, 2002, 33 (1):157-165.
|
| [10] |
Francis JM,Beck LH Jr,Salant DJ. Membranous nephropathy: a journey frombench to bedside[J]. Am J Kidney Dis, 2016, 68(1):138-147.
|
| [11] |
Qin W,Beck LH Jr,Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy[J]. J Am Soc Nephrol, 2011, 22(6):1137-1143.
|
| [12] |
Hoxha E,Beck LH Jr,Wiech T, et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7a-specific antibodies in membranous nephropathy[J]. J Am Soc Nephrol, 2016, 28(2):520-531.
|
| [13] |
Deegens JK,Wetzels JF. Membranous Nephropathy in the older adult: epideiology, diagnosis and management[J]. Drugs Aging, 2007, 24(9):717-732.
|
| [14] |
KDIGO. KDIGO clinical practice guidefine for glomerulonephritis[J]. Kidney Int Suppl, 2012, 2(2):139-274.
|
| [15] |
Gekle M. Kidney and aging-A narrative review[J]. Exp Gerontol, 2017, 87(Pt B):153-155.
|
| [16] |
Dahan K,Debjec H,Plaisier E, et al. Rituximab for severemembranous nephropathy: a 6-month trial with extended follow-up[j]. J Am Soc Nephrol, 2017, 28(1):348-358.
|
| [17] |
Mak SK,Lo KY,Wong CY, et al. Treatment with cyclophosphamide in elderly-onset nephrotic syndrome[J]. Nephron Clin Pract, 2005, 101(1):25-32.
|
| [18] |
Li MX,Yu YW,Zhang ZY, et al. Administration of low-dose cyclosporine alone for the treatment of elderly patients withmembranous nephropathy[J]. Genet Mol Res, 2015, 14(1):2665-2673.
|
| [19] |
Deegen JK,Wetzels JF. Membranous nephropathy in the older adult: epideiology, diagnosis and management[J].Drugs Aging, 2007, 24(9):717-732.
|